Open Access Repository

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia

Downloads

Downloads per month over past year

Larance, B, Degenhardt, L, Grebely, J, Nielsen, S, Bruno, R ORCID: 0000-0001-6673-833X, Dietze, P, Lancaster, K, Larney, S, Santo, T, Shanahan, M, Memedovic, S, Ali, R and Farrell, M 2019 , 'Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia' , Addiction , pp. 1-11 , doi: 10.1111/add.14941.

[img]
Preview
PDF (Published version)
138023 - percep...pdf | Download (655kB)

| Preview

Abstract

Aims: To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia. Design: Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australiain November 2018. Setting Sydney, Melbourne and Hobart. Participants: A total of 402 people who regularly useopioids interviewed December 2017 to March 2018. Measurements: Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthlyinjections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosingsetting, unsupervised doses, out-of-pocket expenses and travel distance). Findings: Sixty-eight per cent [95% confidenceinterval (CI) = 63–73%] believed XR-buprenorphine was a good treatment option for them. They were more likely to report being younger [26–35 versus > 55 years; odds ratio (OR) = 3.16, 95% CI = 1.12–8.89; P = 0.029], being female(OR = 1.67, 95% CI = 1.04–2.69; P = 0.034), P =0.016) and past-month heroin (OR = 1.81, 95% CI = 1.15–2.85; P = 0.006) and methamphetamine use (OR = 1.90,95% CI = 1.20–3.01; P = 0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% preferred weekly and 39% preferred monthly. Among OAT recipients (n = 255), believing XR-buprenorphine was a goodtreatment option was associated with shorter treatment episodes (1–2 versus ≥ 2 years; OR = 3.93, 95% CI = 1.26–12.22; P = 0.018), fewer unsupervised doses (≤ 8 doses past-month versus no take-aways; OR = 0.50; 95% CI = 0.27–0.93; P = 0.028) and longer travel distance (≥ 5 versus P = 0.009). Sixtynine per cent reported ‘no problems or concerns’ with potential differences in availability, flexibility and location of XRbuprenorphine. Conclusions: Among regular opioid users in Australia, perceptions of extended-release buprenorphineas a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)convenience of current opioid agonist treatment.

Item Type: Article
Authors/Creators:Larance, B and Degenhardt, L and Grebely, J and Nielsen, S and Bruno, R and Dietze, P and Lancaster, K and Larney, S and Santo, T and Shanahan, M and Memedovic, S and Ali, R and Farrell, M
Keywords: buprenorphine depot, buprenorphine injection, depot preparations, medication-assisted treatment, patient preferences, opioiduse disorder
Journal or Publication Title: Addiction
Publisher: Wiley-Blackwell
ISSN: 0965-2140
DOI / ID Number: 10.1111/add.14941
Copyright Information:

© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, https://creativecommons.org/licenses/by-nc/4.0/ which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP